Risk-benefit perspectives in COX-2 blockade

Current Drug Safety

Volumn 3, Issue 1, 2008, Pages 14-23

  Dabu Bondoc, Susan ^a   Franco, Samantha ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

COX 2 inhibition; COX 2 selective inhibitor; COX 2 specific inhibitor; COX blockade; Coxibs; Endothelial dysfunction; Gastrointestinal toxicity; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ARACHIDONIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIURETIC AGENT; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MEMBRANE PHOSPHOLIPID; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PARECOXIB; PHOSPHOLIPASE A2; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTANOID; ROFECOXIB; THROMBOXANE A2; UNINDEXED DRUG; VALDECOXIB;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE MODEL; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EDEMA; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL SYMPTOM; GOUT; HEART ARREST; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; OSTEOARTHRITIS; PEPTIC ULCER BLEEDING; PHARMACODYNAMICS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; HUMANS; PAIN, POSTOPERATIVE; RISK ASSESSMENT;

EID: 38949087467     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488608783333970     Document Type: Review

References (73)

1. Fauler J. Undesired effects of NSAIDS and coxibs. MMW Fortschr Med 2005; 147(31-32): 31-35.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340(24): 1888-1899.
3. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124(2): 288-292.
4. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268(9): 6610-6614.
5. Kargman S, Charleson S, Cartwright M, et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111(2): 445-454.
6. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 1520-8.
7. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284(10): 1247-1255.
8. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364(9435): 665-674.
9. Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98(8): 1725-1733.
10. Lewis JD, Kimmel SE, Localio AR, et al. Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 129(6): 1865-1874.
11. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325(7365): 624.
12. Capone ML, Tacconelli S, Sciulli MG, Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003; 16(2 Suppl): 49-58.
13. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130(1): 55-64.
14. Bolten WW. Problem of the atherothrombotic potential of nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65(1): 7-13.
15. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352(11): 1092-1102.
16. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352(11): 1071-1080.
17. Finckh A, Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann Intern Med 2005; 142(3): 212-214.
18. Levin B. Celecoxib in adenoma prevention: The PreSAP Trial. FDA Advisory Committee on Cox-2 Inhibitors and NSAIDs. 2005 [cited 16-18 February 2005]. Available from: http://www.fda.gov/ohrms/dockets/ac/05/slides/ 2005-4090S109FDA-Levin.PPT, accessed 19 August 2006.
19. NIH. Use of non-steroidal anti-inflammatory suspended in large Alzheimer's disease prevention trial. 2004 [cited 9 January 2005]. Available from: http://www.nih.gov/news/pr/dec2004/ad-20.htm, accessed 12 October 2005.
20. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364(9450): 2021-2029.
21. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302-1308.
22. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363(9423): 1751-1756.
23. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359(9301): 118-123.
24. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365(9458): 475-481.
25. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068-2073.
26. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98(3): 266-274.
27. Bishop-Bailey D, Mitchell JA, Warner TD. COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Biol 2006; 26(5): 956-958.
28. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125(6): 1481-1492.
29. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352(11): 1081-1091.
30. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364(9435): 675-684.
31. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368(9549): 1771-1781.
32. Capone ML, Tacconelli S, Patrignani P. Clinical pharmacology of etoricoxib. Expert Opin Drug Metab Toxicol 2005; 1(2): 269-282.
33. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111(3): 334-342.
34. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96(1): 272-277.
35. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003; 42(10): 1747-1753.
36. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116(1): 4-15.
37. King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006; 26(5): 1137-1143.
38. Mezzetti A. Pharmacological modulation of plaque instability. Lupus 2005; 14(9): 769-772.
39. Cipollone F, Fazia ML, Iezzi A, et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 2005; 25(9): 1925-1931.
40. Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100(1): 48-54.
41. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 2002; 106(2): 191-195.
42. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142(3): 157-164.
43. Whelton A. The coxib conundrum: lessons from the rise and fall of rofecoxib. Am J Ther 2004; 11(6): 417-421.
44. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163(4): 481-486.
45. Mason RP, Walter MF, McNulty HP, et al. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. J Cardiovasc Pharmacol 2006; 47(Suppl 1): S7-14.
46. Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108(19): 2308-2311.
47. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102(8): 840-845.
48. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107(3): 405-409.
49. Egan K, FitzGerald GA. Eicosanoids and the vascular endothelium. Handb Exp Pharmacol 2006; (176 Pt 1): 189-211.
50. Justice E, Carruthers DM. Cardiovascular risk and COX-2 inhibition in rheumatological practice. J Hum Hypertens 2005; 19(1): 1-5.
51. Langman MJ, Eichler HG, Mavros P, Watson DJ, Kong SX. Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs. Int J Clin Pharmacol Ther 2004; 42(5): 260-266.
52. Kramer BK, Kammerl MC, Komhoff M. Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications. Kidney Blood Press Res 2004; 27(1): 43-62.
53. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006; 92(11): 1610-1615.
54. Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 2004; 13(6): 339-343.
55. Alper AB Jr, Tomlin H, Sadhwani U, Whelton A, Puschett J. Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial. Am J Ther 2006; 13(3): 229-235.
56. Hermann M, Shaw S, Kiss E, et al. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 2005; 45(2): 193-197.
57. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109(12): 1468-1471.
58. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol. 2004; 43(6): 985-990.
59. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25): 1809-1817.
60. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109(24): 3000-3006.
61. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347(26): 2104-2110.
62. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006; 55(12): 1731-1738.
63. Sinatra R. Role of COX-2 inhibitors in the evolution of acute pain management. J Pain Symptom Manage 2002; 24(1 Suppl): S18-27.
64. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000; 91(5): 1221-1225.
65. Reuben SS, Ekman EF, Raghunathan K, Steinberg RB, Blinder JL, Adesioye J. The effect of cyclooxygenase-2 inhibition on acute and chronic donor-site pain after spinal-fusion surgery. Reg Anesth Pain Med 2006; 31(1): 6-13.
66. Reuben SS, Fingeroth R, Krushell R, Maciolek H. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002; 17(1): 26-31.
67. Gimbel JS, Brugger A, Zhao W, Verburg KM, Geis GS. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001; 23(2): 228-241.
68. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287(1): 64-71.
69. Sinatra RS, Boice JA, Loeys TL, et al. Evaluation of the effect of perioperative rofecoxib treatment on pain control and clinical outcomes in patients recovering from gynecologic abdominal surgery: a randomized, double-blind, placebo-controlled clinical study. Reg Anesth Pain Med 2006; 31(2): 134-142.
70. Sinatra RS, Shen QJ, Halaszynski T, Luther MA, Shaheen Y. Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: the effects on effort-dependent pain and pulmonary function. Anesth Analg 2004; 98(1): 135-40.
71. Issioui T, Klein KW, White PF, et al. Cost-efficacy of rofecoxib versus acetaminophen for preventing pain after ambulatory surgery. Anesthesiology 2002; 97(4): 931-937.
72. Reuben SS, Buvanendran A, Kroin JS, Steinberg RB. Postoperative modulation of central nervous system prostaglandin E2 by cyclooxygenase inhibitors after vascular surgery. Anesthesiology 2006; 104(3): 411-416.
73. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348(10): 891-899.